APLT Applied Therapeutics

Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference

Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.

A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at . A replay of the webcast will be archived on the Company’s website for 90 days following the event.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

To learn more, please visit and follow the company on Twitter @Applied_Tx.

Contacts

Investors:

Julie Seidel/Andrew Vulis

646-970-0543

Media:



EN
05/11/2024

Underlying

APLTApplied Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Applied Therapeutics

 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financia...

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results -  Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full yea...

April 14, 2025 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Files Form 12b-25 with the Securities and Exchang...

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b...

March 31, 2025 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Re...

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer Dr. Baumgartner will advance Applied’s preparation for upcoming regulatory interactions NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company’s executive leadership team and will be responsible for leading Applied’s global regulatory s...

March 19, 2025 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President a...

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industries NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceuti...

January 21, 2025 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Applied Therapeutics Appoints John H. Johnson as Executive Chairman Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana S...

December 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch